Insta
US-Based Novavax Begins Clinical Trials Of Its COVID-19 Vaccine Candidate On Adolescents Aged Between 12 To 17 Years
Source: Novavax's official Twitter handle
In a major development, United States (US) based biotechnology and pharmaceutical major Novavax has started the clinical trials of its proposed COVID-19 vaccine on children, reports Hindustan Times.
The trials would involve as many as 3,000 adolescents aged between 12-17 years. The trials would test the efficacy and safety of the vaccine, with participants receiving either the vaccine candidate or placebo in two doses, 21 days apart. Following this, the participants will be monitored for up to two years.
It should be noted that as of now, the Novavax vaccine has not yet been authorised in any country, including for adults. However, the company is said to be planning to file for emergency authorization in the United Kingdom (UK) in the second quarter of 2021, followed by in the US.
At the end of January, the company had announced that in its UK trials involving 15,000 adults, the vaccine developed by it showed an efficacy of 89.3 per cent against COVID-19. Meanwhile, Moderna, Johnson & Johnson and Pfizer are also conducting trials in adolescents.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest
